Carolyn Cameron, MPH

Director
MSD Australia, Australia

Disclosure(s): MSD Australia: employee, Stocks/Bonds (Private Company)

Poster(s):

• (P-282) Cost Effectiveness Analysis of Ceftolozane/Tazobactam for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in the Philippines
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT